145 related articles for article (PubMed ID: 15803099)
1. [Acronycine revisited: development of benzo[b]acronycine antitumor agents].
Tillequin F; Koch M
Ann Pharm Fr; 2005 Jan; 63(1):35-43. PubMed ID: 15803099
[TBL] [Abstract][Full Text] [Related]
2. [Structure activity relationships and mechanism of action of antitumor benzo[b]acronycine antitumor agents].
Seguin E; Tillequin F
Ann Pharm Fr; 2005 Jan; 63(1):44-52. PubMed ID: 15803100
[TBL] [Abstract][Full Text] [Related]
3. [New antitumor agents in the acronycine series].
Tillequin F
Ann Pharm Fr; 2002 Jul; 60(4):246-52. PubMed ID: 12378151
[TBL] [Abstract][Full Text] [Related]
4. Acronycine derivatives: a promising series of anticancer agents.
Nguyen QC; Nguyen TT; Yougnia R; Gaslonde T; Dufat H; Michel S; Tillequin F
Anticancer Agents Med Chem; 2009 Sep; 9(7):804-15. PubMed ID: 19594412
[TBL] [Abstract][Full Text] [Related]
5. Benzo[b]acronycine derivatives: a novel class of antitumor agents.
Michel S; Gaslonde T; Tillequin F
Eur J Med Chem; 2004 Aug; 39(8):649-55. PubMed ID: 15276298
[TBL] [Abstract][Full Text] [Related]
6. [From acronycine to benzo-[b]-acronycine derivatives: potent antitumor agents].
Koch M
Bull Acad Natl Med; 2007 Jan; 191(1):83-91; discussion 91-3. PubMed ID: 17645109
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and cytotoxic and antitumor activity of 1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine diacid hemiesters and carbamates.
Doan Thi Mai H; Gaslonde T; Michel S; Koch M; Tillequin F; Pfeiffer B; Renard P; Kraus-Berthier L; Léonce S; Pierré A
Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):293-7. PubMed ID: 14993749
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships in the acronycine series.
Michel S; Seguin E; Tillequin F
Curr Med Chem; 2002 Sep; 9(18):1689-700. PubMed ID: 12171551
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships and mechanism of action of antitumor benzo[b]pyrano[3,2-h]acridin-7-one acronycine analogues.
Thi Mai HD; Gaslonde T; Michel S; Tillequin F; Koch M; Bongui JB; Elomri A; Seguin E; Pfeiffer B; Renard P; David-Cordonnier MH; Laine W; Bailly C; Kraus-Berthier L; Léonce S; Hickman JA; Pierré A
J Med Chem; 2003 Jul; 46(14):3072-82. PubMed ID: 12825945
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships in the acronycine and benzo[b]acronycine series: role of the pyran ring.
Do Q; Thi Mai HD; Gaslonde T; Pfeiffer B; Léonce S; Pierré A; Michel S; Tillequin F; Dufat H
Eur J Med Chem; 2008 Dec; 43(12):2677-87. PubMed ID: 18342404
[TBL] [Abstract][Full Text] [Related]
11. Chiral dihydroxylation of acronycine: absolute configuration of natural cis-1,2-dihydroxy-1,2-dihydroacronycine and cytotoxicity of (1R,2R)- and (1S,2S)-1,2-diacetoxy-1,2-dihydroacronycine.
Costes N; Michel S; Tillequin F; Koch M; Pierré A; Atassi G
J Nat Prod; 1999 Mar; 62(3):490-2. PubMed ID: 10096866
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and cytotoxic and antitumor activity of benzo[b]pyrano[3, 2-h]acridin-7-one analogues of acronycine.
Costes N; Le Deit H; Michel S; Tillequin F; Koch M; Pfeiffer B; Renard P; Léonce S; Guilbaud N; Kraus-Berthier L; Pierré A; Atassi G
J Med Chem; 2000 Jun; 43(12):2395-402. PubMed ID: 10882366
[TBL] [Abstract][Full Text] [Related]
13. Antitumor psoropermum xanthones and sarcomelicope acridones: privileged structures implied in DNA alkylation.
Nguyen HT; Lallemand MC; Boutefnouchet S; Michel S; Tillequin F
J Nat Prod; 2009 Mar; 72(3):527-39. PubMed ID: 19191562
[TBL] [Abstract][Full Text] [Related]
14. Acronycine derivatives as promising antitumor agents.
Guilbaud N; Léonce S; Tillequin F; Koch M; Hickman JA; Pierré A
Anticancer Drugs; 2002 Jun; 13(5):445-9. PubMed ID: 12045455
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and cytotoxic activity of benzo[a]acronycine and benzo[b]acronycine substituted on the A ring.
Gaslonde T; Covello F; Velazquez-Alonso L; Léonce S; Pierré A; Pfeiffer B; Michel S; Tillequin F
Eur J Med Chem; 2011 May; 46(5):1861-73. PubMed ID: 21411193
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.
Elomri A; Mitaku S; Michel S; Skaltsounis AL; Tillequin F; Koch M; Pierré A; Guilbaud N; Léonce S; Kraus-Berthier L; Rolland Y; Atassi G
J Med Chem; 1996 Nov; 39(24):4762-6. PubMed ID: 8941390
[TBL] [Abstract][Full Text] [Related]
17. Influence of the stereoisomeric position of the reactive acetate groups of the benzo[b]acronycine derivative S23906-1 on its DNA alkylation, helix-opening, cytotoxic, and antitumor activities.
Depauw S; Gaslonde T; Léonce S; Kraus-Berthier L; Laine W; Lenglet G; Chiaroni A; Pfeiffer B; Bailly C; Michel S; Tillequin F; Pierré A; David-Cordonnier MH
Mol Pharmacol; 2009 Dec; 76(6):1172-85. PubMed ID: 19752199
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and cytotoxic activity of benzophenanthrolinone analogues of acronycine.
Bongui JB; Elomri A; Seguin E; Tillequin F; Pfeiffer B; Renard P; Pierré A; Atassi G
Chem Pharm Bull (Tokyo); 2001 Sep; 49(9):1077-80. PubMed ID: 11558589
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the cytotoxic mechanisms mediated by the broad-spectrum antitumor alkaloid acronycine and selected semisynthetic derivatives.
Shieh HL; Pezzuto JM; Cordell GA
Chem Biol Interact; 1992 Jan; 81(1-2):35-55. PubMed ID: 1730147
[TBL] [Abstract][Full Text] [Related]
20. 2,2-dimethyl-2H-pyran-derived alkaloids I. Practical synthesis of acronycine and benzo[b]acronycine and their biological properties.
Motiur Rahman AF; Liang JL; Lee SH; Son JK; Jung MJ; Kwon Y; Jahng Y
Arch Pharm Res; 2008 Sep; 31(9):1087-93. PubMed ID: 18806949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
